vs

Side-by-side financial comparison of BlackSky Technology Inc. (BKSY) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $35.2M, roughly 1.1× BlackSky Technology Inc.). On growth, BlackSky Technology Inc. posted the faster year-over-year revenue change (15.9% vs -57.1%). Over the past eight quarters, BlackSky Technology Inc.'s revenue compounded faster (20.5% CAGR vs -46.5%).

BlackSky Technology Inc. is a leading geospatial intelligence provider operating a constellation of high-revisit small Earth observation satellites. It delivers real-time satellite imagery, advanced data analytics, and dynamic monitoring solutions to government, defense, critical infrastructure, and commercial clients globally to support data-driven operational decision-making.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

BKSY vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.1× larger
ORGO
$37.2M
$35.2M
BKSY
Growing faster (revenue YoY)
BKSY
BKSY
+73.0% gap
BKSY
15.9%
-57.1%
ORGO
Faster 2-yr revenue CAGR
BKSY
BKSY
Annualised
BKSY
20.5%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BKSY
BKSY
ORGO
ORGO
Revenue
$35.2M
$37.2M
Net Profit
$-868.0K
Gross Margin
30.8%
Operating Margin
-11.8%
-185.1%
Net Margin
-2.5%
Revenue YoY
15.9%
-57.1%
Net Profit YoY
95.5%
EPS (diluted)
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKSY
BKSY
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$35.2M
$225.6M
Q3 25
$19.6M
$150.9M
Q2 25
$22.2M
$101.0M
Q1 25
$29.5M
$86.7M
Q4 24
$30.4M
$126.7M
Q3 24
$22.5M
$115.2M
Q2 24
$24.9M
$130.2M
Net Profit
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
$-868.0K
$43.7M
Q3 25
$-15.3M
$21.6M
Q2 25
$-41.2M
$-9.4M
Q1 25
$-12.8M
$-18.8M
Q4 24
$-19.4M
$7.7M
Q3 24
$-12.6M
$12.3M
Q2 24
$-9.4M
$-17.0M
Gross Margin
BKSY
BKSY
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
BKSY
BKSY
ORGO
ORGO
Q1 26
-185.1%
Q4 25
-11.8%
28.1%
Q3 25
-85.8%
13.7%
Q2 25
-62.8%
-12.5%
Q1 25
-40.5%
-30.9%
Q4 24
-20.0%
8.1%
Q3 24
-58.7%
5.4%
Q2 24
-47.0%
-10.7%
Net Margin
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
-2.5%
19.4%
Q3 25
-78.2%
14.3%
Q2 25
-185.8%
-9.3%
Q1 25
-43.4%
-21.7%
Q4 24
-63.9%
6.1%
Q3 24
-55.8%
10.7%
Q2 24
-37.7%
-13.1%
EPS (diluted)
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
$0.04
$0.31
Q3 25
$-0.44
$0.11
Q2 25
$-1.27
$-0.10
Q1 25
$-0.42
$-0.17
Q4 24
$-0.61
$0.05
Q3 24
$-0.66
$0.09
Q2 24
$-0.52
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKSY
BKSY
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$124.5M
$91.4M
Total DebtLower is stronger
$201.1M
Stockholders' EquityBook value
$94.9M
Total Assets
$386.2M
$520.0M
Debt / EquityLower = less leverage
2.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKSY
BKSY
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$124.5M
$93.7M
Q3 25
$146.5M
$63.7M
Q2 25
$93.8M
$73.1M
Q1 25
$75.8M
$110.0M
Q4 24
$52.5M
$135.6M
Q3 24
$63.2M
$94.3M
Q2 24
$41.2M
$89.9M
Total Debt
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
$201.1M
Q3 25
$195.1M
Q2 25
$122.5M
Q1 25
$115.3M
Q4 24
$107.7M
Q3 24
$98.8M
$62.3M
Q2 24
$108.6M
$63.8M
Stockholders' Equity
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
$94.9M
$300.1M
Q3 25
$91.1M
$255.1M
Q2 25
$86.6M
$233.2M
Q1 25
$88.8M
$242.9M
Q4 24
$94.0M
$262.9M
Q3 24
$110.3M
$278.5M
Q2 24
$76.5M
$263.5M
Total Assets
BKSY
BKSY
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$386.2M
$598.7M
Q3 25
$380.9M
$509.8M
Q2 25
$310.8M
$461.1M
Q1 25
$284.9M
$467.4M
Q4 24
$254.1M
$497.9M
Q3 24
$245.5M
$446.3M
Q2 24
$224.3M
$443.2M
Debt / Equity
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
2.12×
Q3 25
2.14×
Q2 25
1.41×
Q1 25
1.30×
Q4 24
1.15×
Q3 24
0.90×
0.22×
Q2 24
1.42×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKSY
BKSY
ORGO
ORGO
Operating Cash FlowLast quarter
$-9.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
$-9.3M
$39.4M
Q3 25
$-39.0M
$3.1M
Q2 25
$-7.3M
$-32.9M
Q1 25
$27.2M
$-19.9M
Q4 24
$-1.8M
$10.9M
Q3 24
$1.0M
$8.7M
Q2 24
$-1.8M
$4.7M
Free Cash Flow
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
BKSY
BKSY
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons